14.3.3 protein eta or 14.3.3  binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner (Ref SwissProt). 14.3.3 protein eta is widely expressed as both homodimers and heterodimers and are concentrated in the nervous system. High concentrations of 14.3.3 protein eta have been linked to Creutzfeld Jacob Disease, Parkinson's Disease and early-onset schizopherenia.

Antibody recognizes 14.3.3 protein by western blot, immunocytochemistry on acetone or 4% PFA fixed cells, or frozen tissues, not yet tested on paraffin fixed tissues. Approved applicaitons include: WB, IHC/IF. Suggested dilution of 1:500-1:1,000 for IHC/IF. Suggested dilution of 1:1,000-1:5,000 for WB. A suitable control tissue is rat spinal cord or peripheral nerve homogenate.
Application Information:
WB, IHC/IF. Suggested dilution of 1:500-1:1,000 for IHC/IF. Suggested dilution of 1:1,000-1:5,000 for WB. A suitable control tissue is rat spinal cord or peripheral nerve homogenate.

Type: Primary
Antigen: 14-3-3
Clonality: Monoclonal
Clone: 3G12
Conjugation: Unconjugated
Epitope:
Host: Mouse
Isotype: IgG
Reactivity: Human, Rat